| Name | Author | |
|
Biomarkers and surrogate endpoints are becoming an important part of regulatory submissions and this is driving the development of medical imaging in clinical trials. The author discusses the main imaging technologies and their value in assessing new trea…
|
Dr. Oliver Bohnsack, Associate Medical Director, Perceptive Informatics |
|
A changing regulatory environment and difficult targets present significant challenges for biopharmaceutical companies seeking a balanced approach to risk management.
|
Nayan Nanavati, Vice President, Peri-Approval Clinical Excellence, Americas |
|
In the current competitive global market, you need uncomplicated access to a comprehensive breadth of services no matter your company size, global needs or therapeutic focus.
|
|
|
A survey produced by health industry insights, an IDC company and sponsored by PAREXEL reported that the top three most important companies in working with performance metrics for biopharmaceutical companies in working with clinical research organizations…
|
Joshua Schultz, Vice President of Clinical Research Services, PAREXEL International |
|
Web-based forums allow ongoing contact with key opion leaders-on their schedule
For most pharma companies, key opinion leaders (KOLs) have become an increasingly important part of the team, throughout the entire lifecycle of product development. And at e…
|
Alain Eudaric and Mike Gauthier of eTractions |
|
Proactive risk management helps pharma protect their product development investments and futures. Proactive risk management is absolutely vital for every organization in today's fast moving global marketplace. As the recent worldwide financial crisis clea…
|
Holger Liebig and Rebecca Hastings |
|
The biopharmaceutical industry has been relatively slow to embrace the advantages of long-term strategic partnerships that have benefited many other industries. Until recently, the majority of relationships between biopharmaceutical companies and CROs or…
|
Joshua Schultz |